Synergism between topiramate and budipine in refractory status epilepticus in the rat

Epilepsia

Volumn 45, Issue 11, 2004, Pages 1300-1307

  Fisher, Andrew ^a   Wang, Xiaolan ^a   Cock, Hannah R ^a   Thom, Maria ^a   Patsalos, Philip N ^a   Walker, Matthew C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Budipine; Neuroprotection; Perforant path; Status epilepticus; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; BUDIPINE; HALOTHANE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TOPIRAMATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ELECTRODE; ELECTROENCEPHALOGRAPHY; ELECTROSTIMULATION; EPILEPTIC STATE; HIPPOCAMPUS; HISTOPATHOLOGY; MALE; NEUROPROTECTION; NONHUMAN; PERFORANT NERVE TRACT; PRIORITY JOURNAL; RAT; RAT STRAIN;

ANIMALS; ANTICONVULSANTS; CELL DEATH; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTRIC STIMULATION; ELECTRODES, IMPLANTED; ELECTROENCEPHALOGRAPHY; FRUCTOSE; HUMANS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; PERFORANT PATHWAY; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; STATUS EPILEPTICUS;

EID: 7944226503     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2004.26404.x     Document Type: Article

References (50)

1. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus: Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;339:792-8.
2. Sloviter RS. "Epileptic" brain damage in rats induced by sustained electrical stimulation of the perforant path, I: acute electrophysiological and light microscopic studies. Brain Res Bull 1983;10:675-97.
3. A receptors. J Neurosci 1997;17:7532-40.
4. Mazarati AM, Baldwin RA, Sankar R, et al. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res 1998;814:179-85.
5. Claassen J, Hirsch LJ, Emerson RG, et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002;43:146-53.
6. Walker MC. Status epilepticus on the intensive care unit. J Neurol 2003;250:401-6.
7. Meldrum BS. Excitatory amino acid receptors and their role in epilepsy and cerebral ischaemia. Ann N Y Acad Sci 1995;757:492-505.
8. Clifford DB, Olney JW, Benz AM, et al. Ketamine, phencyclidine, and MK801 protect against kainic acid-induced seizure-related brain damage. Epilepsia 1990;31:382-90.
9. Fariello RG, Golden GT, Smith GG, et al. Potentiation of kainic acid epileptogenicity and sparing from neuronal damage by an NMDA receptor antagonist. Epilepsy Res 1989;3:206-13.
10. Penix LP, Wasterlain CG. Selective protection of neuropeptide containing dentate hilar interneurons by non-NMDA receptor blockade in an animal model of status epilepticus. Brain Res 1994;644:19-24.
11. Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res 2000;42:117-22.
12. Prasad A, Williamson BA, Bertram EH. Phenobarbital and MK-801, but not phenytoin, improve the long-term outcome of status epilepticus. Ann Neurol 2002;51:175-81.
13. Wallon NY, Treiman DM. Motor and electroencephalographic response of refractory experimental status epilepticus in rats to treatment with MK-801, diazepam, or MK-801 plus diazepam. Brain Res 1991;553:97-104.
14. Rice AC, DeLorenzo RJ. N-methyl-D-aspartate receptor activation regulates refractoriness of status epilepticus to diazepam. Neuroscience 1999;93:117-23.
15. Siegfried J, Fischer R. Budipine: a new chemical substance in the treatment of Parkinson's disease. In: Gerstenbrand F, Poewe W, Stern G, eds. Clinical experiences with budipine in Parkinson therapy. New York: Springer-Verlag, 1985:152-7.
16. Eltze M. Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm 1999(suppl); 56:83-105.
17. Klockgether T, Wüllner U, Steinbach JP, et al. Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur J Pharmacol 1996;301:67-73.
18. Glauser T. Topiramate. Epilepsia 1999;40(suppl 5):S71-80.
19. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-60
20. Holtkamp M, Tong X, Walker MC. Propofol in subanesthetic doses terminates status epilepticus in a rodent model. Ann Neurol 2001;49:260-3.
21. Walker MC, Perry H, Scaravilli F, et al. Halothane as a neuroprotectant during constant stimulation of the perforant path. Epilepsia 1999;40:359-64.
22. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Sydney: Academic Press, 1986.
23. Lee VC, Moscicki JC, DiFazio CA. Propofol sedation produces dose-dependent suppression of lidocaine-induced seizures in rats. Anesth Analg 1998;86:652-57.
24. Racine RJ. Modification of seizure activity by electrical stimulation, II: motor seizure. Electroencephalogr Clin Neurophysiol 1972;32:281-94.
25. Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41(suppl 1):S3-9.
26. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24.
27. Faught E. Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience. Epilepsia 1997;38(suppl 1):S24-7.
28. Coppola G, Caliendo G, Terracciano MM, et al. Topiramate in refractory partial-onset seizures in children, adolescents and young adults: a multicentric open trial. Epilepsy Res 2001;43;255-60.
29. Reuber M, Evans J, Bamford JM. Topiramate in drug-resistant complex partial status epilepticus. Eur J Neurol 2002;9:111-2.
30. Towne AR, Garnett RN, Waterhouse EJ, et al. The use of topiramate in refractory status epilepticus. Neurology 2003;60:332-4.
31. Niebaurer M, Gruenthal M. Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res 1999;837:263-9.
32. Rigoulot MA, Koning E, Ferrandon A, et al. Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy. J Pharmacol Exp Ther 2004;308:787-95.
33. Lee S-R, Kim S-P, Kim J-E. Protective effect of topiramate against hippocampal neuronal damage after global ischaemia in the gerbils. Neurosci Lett 2000;281:183-6.
34. Yang Y, Suaib A, Li Q, et al. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 1998;804:169-76.
35. Brandt C, Potschka H, Loscher W, et al. N-methyl-D-aspartate receptor blockade after status epilepticus protects against limbic brain damage but not against epilepsy in the kainate model of temporal lobe epilepsy. Neuroscience 2003;118:727-40.
36. Meldrum BS, Brierley JB. Prolonged epileptic seizures in primates: ischemic cell change and its relation to ictal physiological events. Arch Neurol 1973;28:10-7.
37. Williamson JM, Lothman EW. The effects of MK801 on kindled seizures: implications for use and limitations as an antiepileptic drug. Ann Neurol 1989;26:85-90.
38. Carter A. Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbances of motor coordination. J Pharmacol Exp Ther 1994;269:573-80.
39. Geter-Douglass B, Witkin JM. Behavioural effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology 1999;146:280-9.
40. Parsons CG, Quack G, Bresink I, et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995;34:1239-58.
41. Kornhuber J, Herr B, Thome J, et al. The antiparkinsonian drug budipine binds to NMDA and sigma receptors in post-mortem brain tissue. J Neural Transm Suppl 1995;46:131-7.
42. Jellinger K, Bliesath H. Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo. J Neurol 1987;234:280-2.
43. Parsons CG, Hartmann S, Spielmanns P. Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones. Neuropharmacology 1998;37:719-27.
44. MacDonald JF, Bartlett MC, Mody I, et al. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J Physiol 1991;432:483-508.
45. Przuntek H, Stasch JP. Biochemical and pharmacologic aspects of the mechanism of action of budipine. In: Gerstenbrand F, Poewe W, Stern G, eds. Clinical experiences with budipine in Parkinson therapy. New York: Springer-Verlag, 1985:107-12.
46. Biggs CS, Fisher A, Starr MS. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra. Synapse 1998;30:309-17.
47. Biggs CS, Starr MS. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-Dopa-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum. Synapse 1999;34:36-46.
48. 5 receptors. Naunyn Schmiedeberg Arch Pharmacol 1998;357(suppl S):79.
49. Mihatsch W, Russ H, Przuntek H. Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl and 1-t-butyl-4,4-diphenylpiperidine. J Neural Transm 1988;71:177-88.
50. Jackisch R, Huang HY, Reimann W, et al. Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissues in vitro. J Pharmacol Exp Ther 1993;264:207-11.